AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32271672
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg intravenously once every 3 weeks for up to 24 months
Trial: 36176007
Drug: Mindfulness meditation
RxNorm normalized name: benzalkonium chloride Topical Foam [Meditize]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness meditation program conducted weekly for 12 weeks in addition to usual care
Trial: 33758119
Drug: Substance-exposed newborn
RxNorm normalized name: Vital E- Newborn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substance-exposed newborn vignette with injection heroin use
Trial: 33758119
Drug: Substance-exposed newborn
RxNorm normalized name: Vital E- Newborn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substance-exposed newborn vignette with prescription opioid use
Trial: 34687446
Drug: Fremanezumab (monthly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fremanezumab (monthly or quarterly)
Trial: 38829506
Drug: Anthracycline-based neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthracycline-based neoadjuvant chemotherapy
Trial: 35276884
Drug: Dietary fibre
RxNorm normalized name: Fiore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary fibre supplementation (19.2 g/day) for 2 months
Trial: 35276884
Drug: Non-responders to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-responders to fibre treatment
Trial: 36040741
Drug: Remote care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote care (initial in-home visit followed by daily video visit facilitated by the home hospital nurse)
Trial: 33257104
Drug: Anti-TT IgG
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TT IgG in oral fluid (OF)
Trial: 33257104
Drug: Total IgG
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total IgG in oral fluid specimens
Trial: 33257104
Drug: High oral
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High oral fluid volume and sucking on the swab
Trial: 32135138
Drug: Exenatide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (10 μg subcutaneous injection three times daily for 26 weeks)
Trial: 32135138
Drug: Placebo (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (subcutaneous injection three times daily for 26 weeks)
Trial: 33423267
Drug: CYP3A5 gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: CYP3A5 gene polymorphisms (specifically GG genotype and G allele of rs776746 locus)
Trial: 32712674
Drug: WISCA utilization
RxNorm normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WISCA utilization for empiric antibiotic prescription
Trial: 35012783
Drug: Pemetrexed 500
RxNorm normalized name: pemetrexed 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 plus bevacizumab 15 mg/kg intravenously every 3 weeks for 3 cycles (bevacizumab arm)
Trial: 35012783
Drug: Concurrent thoracic
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent thoracic radiotherapy (TRT) 45 Gy in 25 fractions (TRT arm)
Trial: 33572825
Drug: Rice germ
RxNorm normalized name: RICE GERM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice germ supplementation (25 g twice a day for 4 weeks)
Trial: 33855585
Drug: Sorafenib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib monotherapy
Trial: 35767970
Drug: Jollab (saffron-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jollab (saffron-based beverage) 20 mL three times daily for 4 weeks
Trial: 35767970
Drug: Placebo 20
RxNorm normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 20 mL three times daily for 4 weeks
Trial: 32921111
Drug: Attention and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attention and Interpretation Therapy (AIT) for 10 weeks
Trial: 32239984
Drug: Mild cleanser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild cleanser and moisturizer used twice daily for two weeks
Trial: 34262611
Drug: Sodium picosulfate,
RxNorm normalized name: sodium picosulfate, combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium picosulfate, magnesium oxide, and citric acid (SPMC) oral solution bowel preparation
Trial: 33530186
Drug: Standardized comprehensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized comprehensive western medicine treatment and routine care
Trial: 32621885
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH), median duration 6.2 months (IQR 2.5-12.7)
Trial: 32621885
Drug: Warfarin, median
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin, median duration 2.2 years (IQR 0.9-7.1)
Trial: 32621885
Drug: Secondary thromboprophylaxis
RxNorm normalized name: Secondary potassium phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secondary thromboprophylaxis with warfarin
Trial: 38564986
Drug: Enasidenib monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enasidenib monotherapy
Trial: 39075156
Drug: Sham manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham manual therapy (control)
Trial: 35152531
Drug: Topical flutamide
RxNorm normalized name: Flutamide
DrugBank: Flutamide (DB00499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical flutamide plus 5% minoxidil
Trial: 35236353
Drug: Intervention: Physician
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention: Physician office reception staff inviting patients to register on a tablet in the waiting room.
Trial: 36336249
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose digital health intervention (1 session)
Trial: 36336249
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose digital health intervention (12 sessions)
Trial: 35449109
Drug: Conventional rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional rehabilitation therapies (CRTs) (40 min per day, 6 days per week, for 3 weeks)
Trial: 36334236
Drug: Ustekinumab 45/90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab 45/90 mg
Trial: 33473026
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination technique (acute normovolemic hemodilution, retrograde autologous priming, integrated arterial filter oxygenator)
Trial: 34801263
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with clinical T1 through T2 N+ cancer who underwent neoadjuvant therapy plus surgery
Trial: 35532966
Drug: Web-based, self-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based, self-administered Stop and Go Switching Task
Trial: 35532966
Drug: Web-based, self-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based, self-administered Figure Identification test
Trial: 32054473
Drug: Targeted lung
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted lung denervation (TLD) combined with optimal medical therapy
Trial: 33757723
Drug: Insulin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (20 U/0.5 mL administered intranasally for 2 days prior to surgery)
Trial: 33757723
Drug: Control (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0.5 mL saline administered intranasally for 2 days prior to surgery)
Trial: 32706738
Drug: REACH text
RxNorm normalized name: beach strawberry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REACH text message intervention (daily texts for first 6 months, option to reduce frequency for last 6 months)
Trial: 32706738
Drug: REACH text
RxNorm normalized name: beach strawberry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REACH text message intervention with monthly phone coaching for first 6 months
Trial: 32706738
Drug: Participants who
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants who continued daily text messages for the last 6 months
Trial: 36451389
Drug: Yaobitong capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yaobitong capsule
Trial: 36451389
Drug: Celecoxib capsule
RxNorm normalized name: Celecoxib Capsules
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib capsule
Trial: 34708639
Drug: Songlingxuemaikang (SLXMK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Songlingxuemaikang (SLXMK) 500 mg per capsule, 4500 mg/d, n = 60
Trial: 34708639
Drug: Losartan potassium
RxNorm normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan potassium 50 mg per tablet, 50 mg/d, n = 30
Trial: 32041914
Drug: N-Acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-Acetylcysteine (NAC) supplementation at 600 mg every 8 hours for 3 days
Trial: 35901337
Drug: Short-course radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course radiotherapy with concurrent temozolomide and adjuvant temozolomide
Trial: 34429149
Drug: IV paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV paracetamol (1 g paracetamol + 3.91 g mannitol per 100 mL), n=12
Trial: 34429149
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% Saline 100 mL), n=12
Trial: 35918788
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml levobupivacaine 0.25%
Trial: 35918788
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml levobupivacaine 0.25%
Trial: 32446311
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment plus Liu‐zi‐jue (a mind‐body exercise)
Trial: 32006073
Drug: Non-operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-operative treatment with corticosteroid injections and a controlled strength training program
Trial: 36478142
Drug: BI 187004
RxNorm normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 187004 (20, 80 or 240 mg) as monotherapy
Trial: 36478142
Drug: BI 187004
RxNorm normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 187004 (240 mg) in combination with metformin
Trial: 36478142
Drug: BI 187004
RxNorm normalized name: BI-187004
DrugBank: BI-187004 (DB18897)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 187004 treatment
Trial: 32773602
Drug: Alpha-lipoic acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-lipoic acid (ALA), median maximal tolerated dose 1663 mg/day
Trial: 35534443
Drug: Lactobacillus complex
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus complex capsules (probiotics group)
Trial: 35534443
Drug: Enteric-coated aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated aspirin only (control group)
Trial: 32875383
Drug: DEX 8
RxNorm normalized name: Precedex 80 MCG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX 8 mg plus ETO 300 mg (DEX + ETO)
Trial: 32875383
Drug: DEX 8
RxNorm normalized name: Precedex 80 MCG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX 8 mg (DEX)
Trial: 32875383
Drug: ETO 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETO 300 mg (ETO)
Trial: 32875383
Drug: Control (Paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Paracetamol 750 mg as rescue analgesics)
Trial: 35409460
Drug: Masticatory Muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Masticatory Muscle Training (MaMuT) - part 1: three physiotherapeutic treatments and daily home exercises; part 2: daily home exercises only
Trial: 35851507
Drug: High-dose Vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Vitamin B6 supplementation
Trial: 35851507
Drug: High-dose Vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Vitamin B12 supplementation
Trial: 32899045
Drug: Qishe pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qishe pill
Trial: 33675351
Drug: High-dose FA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose FA (4.0 mg daily)
Trial: 33675351
Drug: Low-dose FA
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose FA (≤1.1 mg daily)
Trial: 36401223
Drug: Lower BW
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower BW (≤ 2500 g)
Trial: 36401223
Drug: Normal BW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal BW (2500 g < BW ≤ 3500 g)
Trial: 36401223
Drug: Higher BW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher BW (> 3500 g)
Trial: 32040379
Drug: Quadrivalent cell-based
RxNorm normalized name: Fluarix Quadrivalent 2018-2019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent cell-based influenza vaccine (QIVc)
Trial: 32343211
Drug: Tablet-based ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based ultrasound (US) for assessing bone age
Trial: 36329602
Drug: 15 g of
RxNorm normalized name: magnesium hydroxide
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 15 g of almond paste and 4 g of inulin
Trial: 32430429
Drug: Total antibody
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total antibody (Ab)
Trial: 33414406
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g tryptophan (Trp-3)
Trial: 33414406
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g tryptophan (Trp-1.5)
Trial: 34180838
Drug: Oral care
RxNorm normalized name: Oral Care Q4 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral care protocol implemented by GPs and nurse practitioners
Trial: 36001498
Drug: XEN gel
RxNorm normalized name: XEN-2174
DrugBank: XEN-2174 (DB05012)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XEN gel stent
Trial: 33377980
Drug: Remote activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote activity monitoring (RAM) system; details on dosage and duration not available.
Trial: 32551912
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet containing background Se only (0.189 mg/kg; C)
Trial: 32551912
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level sodium selenite (0.376 mg/kg; LSS)
Trial: 32551912
Drug: High level
RxNorm normalized name: SODIUM CHLORIDE 5 g in 100 mL TOPICAL LIQUID [SDG high level disinfectant]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High level sodium selenite (0.558 mg/kg; HSS)
Trial: 32551912
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level commercial B Traxim® Se (0.244 mg/kg; LBT)
Trial: 32551912
Drug: High level
RxNorm normalized name: SODIUM CHLORIDE 5 g in 100 mL TOPICAL LIQUID [SDG high level disinfectant]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High level B Traxim® Se (0.448 mg/kg; HBT)
Trial: 32551912
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level selenised yeast (0.290 mg/kg; LSY)
Trial: 32551912
Drug: High level
RxNorm normalized name: SODIUM CHLORIDE 5 g in 100 mL TOPICAL LIQUID [SDG high level disinfectant]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High level selenised yeast (0.487 mg/kg; HSY)
Trial: 36195687
Drug: pepinemab antibody
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pepinemab antibody blockade of SEMA4D
Trial: 34555149
Drug: Ibrexafungerp 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrexafungerp 300 mg BID for 1 day
Trial: 34555149
Drug: Fluconazole 150
RxNorm normalized name: fluconazole 150 MG
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole 150 mg for 1 day
Trial: 35990072
Drug: ABMT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABMT with real self-administered tDCS
Trial: 35990072
Drug: ABMT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABMT with sham self-administered tDCS
Trial: 38606174
Drug: Pharmacist-led medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led medication reconciliation
Trial: 35921643
Drug: Polypharmacy (use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypharmacy (use of >4 drugs daily)
Trial: 34759547
Drug: Fentanyl 2
RxNorm normalized name: fentanyl 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 2 µg/kg i.v.
Trial: 34759547
Drug: Nalbuphine 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine 0.2 mg/kg i.v.
Trial: 35197106
Drug: Mobile technology‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile technology‐based intervention including a personalized website, Fitbit activity tracker and app, individually tailored text messages based on Fitbit data, and daily intervention content on Instagram for 6 months
Trial: 33536672
Drug: Timeliness of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timeliness of treatment initiation
Trial: 33232658
Drug: 0.25% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% ropivacaine with 0.5 mcg/kg clonidine (RC group)
Trial: 33232658
Drug: 0.25% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% ropivacaine with 0.1 mg/kg dexamethasone (RD group)
Trial: 32608944
Drug: Electric toothbrush
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electric toothbrush ("Oral‐B Pro‐Expert, «Procter & Gamble», USA)
Trial: 33904591
Drug: Group assignment
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group assignment (treatment or wait-list control)
Trial: 34514598
Drug: Etesevimab 1400
RxNorm normalized name: Etesevimab
DrugBank: Etesevimab (DB15897)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Etesevimab 1400 mg
Trial: 34252915
Drug: DFN-15 62.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFN-15 62.5 mg
Trial: 34252915
Drug: DFN-15 125
RxNorm normalized name: AVOBENZONE 3 g in 100 mL / HOMOSALATE 10 g in 100 mL / OCTISALATE 5 g in 100 mL / OCTOCRYLENE 5 g in 100 mL TOPICAL LOTION [DFNDR SUNSCREEN SPF 50]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFN-15 125 mg
Trial: 34252915
Drug: DFN-15 250
RxNorm normalized name: AVOBENZONE 3 g in 100 mL / HOMOSALATE 10 g in 100 mL / OCTISALATE 5 g in 100 mL / OCTOCRYLENE 5 g in 100 mL TOPICAL LOTION [DFNDR SUNSCREEN SPF 50]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFN-15 250 mg
Trial: 33292826
Drug: Parent-administered pediatric
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-administered pediatric tuina
Trial: 34107152
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anaesthesia (TIVA) with propofol
Trial: 34107152
Drug: Sevoflurane (SEVO)
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane (SEVO) inhaled anaesthesia
Trial: 35507017
Drug: MEDI0680 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI0680 (20 mg/kg) with durvalumab (750 mg)
Trial: 35507017
Drug: Nivolumab (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (240 mg)
Trial: 35227582
Drug: Repetitive Transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive Transcranial Magnetic Stimulation (rTMS) after a three-week induction treatment and six months of maintenance treatment (three-week periodicity)
Trial: 33938081
Drug: Polish surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polish surface treatment
Trial: 33938081
Drug: Optiglaze surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optiglaze surface treatment
Trial: 33938081
Drug: Polish surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polish surface treatment (all immersion liquids)
Trial: 33938081
Drug: Optiglaze surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optiglaze surface treatment (artificial saliva, tea, and wine)
Trial: 35201358
Drug: Fentanyl (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (1 μg/kg intravenous)